Last update: Nov. 26, 2014
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 32 | % |
Molecular weight | 221 | daltons |
Protein Binding | 20 | % |
VD | 540 | l/Kg |
Tmax | 1,25 (Retard: 3 - 6) | hours |
T1/2 | 4 (Retard: 6) | hours |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche de Euskadi
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Opioid analgesic which is used for treatment of chronic pain.
At latest update, relevant data on its excretion into breast milk were not found.
Despite of a low molecular weight and a low serum-protein binding capacity that would favor excretion into the milk, its high value of volume distribution would permit a shorter permanence in the blood that would hamper its excretion.
A low oral bioavailability would hamper absorption from ingested mother's milk, except among newborn infants o prematures, who may attain an increased absorption capacity.
The risk for the infants would be minimized if the breast feed is avoided within 1 to 4 hours (non-depot formulation), or, within 3 to 6 hours (depot formulation) after taking medication.
Until more information on this drug is available, other options that are known to be safer are recommended, especially when the baby is a newborn or a premature.
Follow-up of symptoms as sedation or gastrointestinal disorders is recommended.